Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk

Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk is a phase 3, randomised interventional study registered as NCT02945033 by University Hospital, Rouen, with a registry enrolment figure of 264 participants, started 2018-07-12 and due to reach its primary completion in 2028-07. Interventions recorded: aspirin intake; placebo intake; Surgical resection of colonic adenocarcinoma stage III or II high risk; Molecular analysis of exon 9 and 20 of PI3K; blood intake. Conditions listed: Colorectal Cancer. Primary outcome: Number of patient with local or distant recurrence or second colorectal cancer or death from any cause, whichever occurred first. Colorectal eligibility wording from the registry: "* Colonic adenocarcinoma stage III". Sites: France. No results are recorded here; the registry entry is the source.